Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI

NCT03370653 is registered in ClinicalTrials.gov with Inventiva Pharma as lead sponsor.

NCT NCT03370653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03370653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI
Lead sponsor
Inventiva Pharma
Phase
Phase 2
Overall status
Completed
Start date
December 30, 2017
Completion date
October 22, 2019
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis vi